SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-118749
Filing Date
2023-11-15
Accepted
2023-11-15 17:02:20
Documents
15
Period of Report
2023-11-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330856d1_8k.htm   iXBRL 8-K 31214
2 EXHIBIT 1.1 tm2330856d1_ex1-1.htm EX-1.1 238664
3 EXHIBIT 5.1 tm2330856d1_ex5-1.htm EX-5.1 11033
7 GRAPHIC tm2330856d1_ex5-1img001.jpg GRAPHIC 1523
  Complete submission text file 0001104659-23-118749.txt   520592

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA acxp-20231115.xsd EX-101.SCH 3024
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20231115_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20231115_pre.xml EX-101.PRE 22365
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2330856d1_8k_htm.xml XML 3317
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 231411387
SIC: 2834 Pharmaceutical Preparations